Can High b-Value Biparametric 3.0 T MRI with Simplified Prostate Image Reporting and Data System (S-PI-RADS) be used in biopsy-naive men?


This article was originally published here

Clin Imaging. June 29, 2021: S0899-7071 (21) 00270-9. doi: 10.1016 / j.clinimag.2021.06.024. Online ahead of print.

ABSTRACT

OBJECTIVE: To analyze the clinical value of high b-value 3.0 T biparametric magnetic resonance with the Simplified Prostate Image Reporting and Data System (S-PI-RADS) in biopsy-naive men.

Methods: A retrospective analysis of data from 224 patients who underwent prostate biopsy (targeted cognitive fusion biopsy combined with systematic biopsy) after 3.0 T high b-value magnetic resonance examination at Haikou Hospital from July 2018 to July 2020 has been carried out. Two radiologists performed multiparametric magnetic resonance imaging (mp-MRI) with the prostate imaging report and data system version 2 (PI-RADS v2) and biparametric magnetic resonance imaging (bp-MRI) with the Simplified Prostate Image Data and Reporting System (S-PI-RADS). The detection efficiency of the two regimens was assessed by classifying prostate cancer (PCa) and clinically significant prostate cancer (csPCa) according to pathology, and the statistical significance of the differences between the two regimens was determined by the Z test.

RESULTS: The area under the receptor operating curve (AUC) values ​​of PI-RADS v2-based mpMRI and S-PI-RADS-based bp-MRI for detecting PCa were respectively 0.905 and 0.892, while the AUC values ​​for the detection of csPCa were respectively 0.919 and 0.906. There was no statistically significant difference between the two tests (Z values ​​were 0.909 and 1.145, p> 0.05).

CONCLUSION: There was no significant difference in the detection efficiency of high b-value bp-MRI based on the S-PI-RADS score for prostate cancer and clinically significant prostate cancer compared to to the standard PI-RADS v2 score with mp-IRM protocols. , which can be applied clinically.

PMID:34243992 | DO I:10.1016 / j.clinimag.2021.06.024


About Hector Hedgepeth

Check Also

New study challenges widely held beliefs about Alzheimer’s disease

A new study challenges the dogma behind drug trials for Alzheimer’s disease. The study found …

Leave a Reply

Your email address will not be published.